Capacity of capecitabine in CRC highlighted by 5-year results

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1609, 2007-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Oral capecitabine preferred in CRC

By  

Inpharma, Vol. 1, Iss. 1529, 2006-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

FDA issues pioglitazone warning based on 5-year study results

By  

Reactions Weekly, Vol. 1, Iss. 1357, 2011-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Capecitabine

By Dooley M.   Goa K.L.  

Drugs, Vol. 58, Iss. 1, 1999-07 ,pp. : 69-76

Adis International

Access to resources Recommend Favorite

Capecitabine: Multifocal leukoencephalopathy: 5 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1089, 2006-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Tamoxifen in the Treatment of Hepatocellular Carcinoma: 5-Year Results of the CLIP-1 Multicentre Randomised Controlled Trial

By  

Current Pharmaceutical Design, Vol. 8, Iss. 11, 2002-05 ,pp. : 1013-1019

Bentham Science Publishers

Access to resources Recommend Favorite